Karyopharm Therapeutics (KPTI) EBT (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly EBT came in at $90.1 million in Q4 2025, up 97.82% YoY from $45.6 million in Q4 2024, and up 372.32% on a QoQ basis from -$33.1 million in Q3 2025.
Karyopharm Therapeutics (KPTI) EBT (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of EBT data on file, last reported at $90.1 million in Q4 2025.
- Quarterly EBT rose 97.82% year-over-year to $90.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.6 million (down 4616.25% YoY) and the FY2025 annual result came in at -$3.6 million, down 4616.25% from the prior year.
- EBT climbed to $90.1 million in Q4 2025, from -$33.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of $101.3 million in Q4 2023 to a low of -$57.3 million in Q1 2021.
- A 5-year average of -$14.6 million and a median of -$34.3 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT jumped 357.64% — and 2025, when it tumbled 255.97%.
- Tracing KPTI's EBT over 5 years: stood at $38.6 million in 2021, then slumped by 201.88% to -$39.3 million in 2022, then jumped by 357.64% to $101.3 million in 2023, then tumbled by 55.04% to $45.6 million in 2024, then jumped by 97.82% to $90.1 million in 2025.
- The last three EBT figures came in at $90.1 million (Q4 2025), -$33.1 million (Q3 2025), and -$37.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | -67.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -67.02 Mn |
| Dec 31, 2025 | 90.12 Mn |
| Sep 30, 2025 | -33.09 Mn |
| Jun 30, 2025 | -37.21 Mn |
| Mar 31, 2025 | -23.43 Mn |
| Dec 31, 2024 | 45.56 Mn |
| Sep 30, 2024 | -32.04 Mn |
| Jun 30, 2024 | 23.86 Mn |
| Mar 31, 2024 | -37.29 Mn |
| Dec 31, 2023 | 101.32 Mn |
| Sep 30, 2023 | -34.49 Mn |
| Jun 30, 2023 | -32.50 Mn |
| Mar 31, 2023 | -34.07 Mn |
| Dec 31, 2022 | -39.33 Mn |
| Sep 30, 2022 | -36.28 Mn |
| Jun 30, 2022 | -48.94 Mn |
| Mar 31, 2022 | -41.27 Mn |
| Dec 31, 2021 | 38.60 Mn |
| Sep 30, 2021 | -51.71 Mn |
| Jun 30, 2021 | -53.45 Mn |